Hydantoin derivatives used as MMP inhibitors

Details for Australian Patent Application No. 2007327105 (hide)

Owner AstraZeneca AB

Inventors Chapman, David; Munck Af Rosenschold, Magnus; Gabos, Balint

Agent Freehills

Pub. Number AU-B-2007327105

PCT Pub. Number WO2008/065393

Priority 60/867,606 29.11.06 US

Filing date 28 November 2007

Wipo publication date 5 June 2008

Acceptance publication date 26 May 2011

International Classifications

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

C07D 239/34 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Event Publications

28 May 2009 PCT application entered the National Phase

  PCT publication WO2008/065393 Priority application(s): WO2008/065393

26 May 2011 Application Accepted

  Published as AU-B-2007327105

22 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007327109-Assay

2007327100-Biogel